1. Home
  2. EXP vs RYTM Comparison

EXP vs RYTM Comparison

Compare EXP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Materials Inc

EXP

Eagle Materials Inc

HOLD

Current Price

$214.29

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$115.63

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXP
RYTM
Founded
1963
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
5.8B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
EXP
RYTM
Price
$214.29
$115.63
Analyst Decision
Hold
Strong Buy
Analyst Count
9
14
Target Price
$227.11
$131.14
AVG Volume (30 Days)
460.6K
640.7K
Earning Date
05-19-2026
05-05-2026
Dividend Yield
0.49%
N/A
EPS Growth
N/A
28.34
EPS
3.29
N/A
Revenue
$495,023,000.00
N/A
Revenue This Year
$1.97
$55.34
Revenue Next Year
$1.95
$86.06
P/E Ratio
$64.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$171.99
$74.50
52 Week High
$245.53
$122.20

Technical Indicators

Market Signals
Indicator
EXP
RYTM
Relative Strength Index (RSI) 49.21 60.52
Support Level $202.41 $98.76
Resistance Level $223.21 $113.03
Average True Range (ATR) 7.94 4.84
MACD 0.79 0.15
Stochastic Oscillator 49.42 98.64

Price Performance

Historical Comparison
EXP
RYTM

About EXP Eagle Materials Inc

Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: